Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — Corporate Update (September 2017)
26 slides from Myriad Genetics's corporate update, Sep 5, 2017
Slide 1: myRisk Hereditary Cancer Enhanced with riskScore
myRisk Hereditary Cancer Enhanced with a Clinically Validated Precision Medicine Tool riskSc@re’ BREAST CANCER
Slide 2: Forward Looking Statements
91% 87% Forward Looking Statements 15M Patient Preventive Care Market Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s curren
Slide 3: The Fourth Epoch in Hereditary Cancer Testing
The Fourth Epoch in Hereditary Cancer Testing
Slide 4: The Problem
The Problem
Slide 5: Myriad Hereditary Cancer Testing: Personalized Medicine for When Decisions Matter
Myriad Hereditary Cancer Testing Personalized Medicine for WHEN DECISIONS MATTER e Answering the , most « pressing question about cancer e
Slide 6: Patients Left Without Answers
a ; @ Patients Left Without Answers @ Positive Despite being at high familial risk 5 for development of breast cancer, 3) Negative fewer than 10% carry a clinically actionable mutation « riskSc@ere
Slide 7: Provider and Patient Left Without a Definitive Answer
CLINICAL UNCERTAINTY Provider and Patient Left Without a Definitive Answer Risk of Breast Cancer 12% Population Risk 87% BRCA Mutation 0% 100%
Slide 8: Only 10% of Patients Tested Are From the Largest Pool
VS Only 10% of Patients Tested Are From the Largest Pool of Patients That Meet Criteria Doctors Focus on “Neon Light” Patients Due to Challenge of Negative Test Report
Slide 9: The Product
The Product
Slide 10: riskScore Breast Cancer
riskScare’ BREAST CANCER riskScore™ is a clinically validated personalized medicine tool that predicts a woman’s lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. riskScore guides medical management in the prevention of breast cancer mor
Slide 11: riskScore Data Shows Test Highly Impactful & Accurate
riskScore Data Shows Test Highly Impactful & Accurate Proprietary score that combines data from >80 single nucleotide polymorphisms (SNPs) with well documented role in predicting cancer risk along with best-in-class family/personal history model (Tyrer-Cuzick model) Results for unaffected patients w
Slide 12: Background Information: What is a SNP and Tyrer-Cuzick?
iA Background Information @ What is a SNP and Tyrer-Cuzick? SNP Tyrer-Cuzick A single nucleotide polymorphism Tyrer-Cuzick is a best-in-class family (SNP) is a variation in a single nucleotide history prediction tool that looks at that occurs at a defined point within family history and personal fac
Slide 13: Advancing Genetic Risk Assessment
Advancing Genetic Risk Assessment BRCA1, BRCA2, TP53, STK11 ATM, CHEK2, PALB2, NBN SNPs Frequency Relative Risk Rare variants (high penetrance) Rare variants (moderate penetrance) Common variants (low penetrance) 1 2 5 ≥10
Slide 14: The Science
The Science
Slide 15: Genome-wide association research and validation studies
Researched 20 years of genome wide association data on SNPs in breast cancer risk Screened > 100,000 patients to select 24,259 patient training study which identified over 80 highly predictive SNPs 10,575 patient validation study showed the SNP panel in riskScore highly predictive of breast cancer r
Slide 16: Risk Distribution From Combined Risk Score
Risk Distribution From Combined Risk Score riskScore Data Shows Test Highly Impactful & Accurate Frequency Patients have a broad distribution of relative risk with many significantly above and below the population risk SNP panel was highly statistically significant for lifetime and breast cancer ris
Slide 17: The Report
The Report
Slide 18: Patient #1 and Patient #2 Reports
Patient #1 ifs Genetic Reet conn 17 zantnf-omamosaea—_fapat Dasa 207 Breast Cancer riskScore™ riskSc@re” RUE 1.2 Fang Lite ik eB Caer ‘ea fk for Brest Cancer Patient #2 mys Gonetie Result Doers tne secon: comeneoa00 Papo Sapt. 2007 Breast Cancer riskScore™ riskSc@re” (<2) 53 est 207 range fo Bes Car
Slide 19: riskScore Example Report
A a @ riskScore Example Report Breast Cancer riskScore™ riskSc@re” BREAST CAN. Provides individual risk score for breast cancer based upon genetic markers and Tyrer-Cuzick "eee @{ 33.7% Breast Cancer riskScore™ - Remaining Lifetime Risk RESULT: 33.7% Remaining Lifetime Risk for Breast Cancer 1.7% 5-
Slide 20: Patient Journey: Early Detection is Key in Preventive Care
— WG Patient Journey: Early Detection is Key in Preventive Care Breast Cancer Screening Guidelines The National Comprehensive Cancer Network and the American Cancer Society recommended annual breast MRI, in addition to mammogram, for women with >20% lifetime risk of breast cancer » riskSc@re’
Slide 21: Advancing the Science with Actionable Results
Advancing the Science with Actionable Results Uncertainty GENETIC TEST RESULT: NEGATIVE ©) MEDICAL MANAGEMENT: * Clinical Breast Exam and Breast Awareness Myriad myRisk® @ © ceneric test RESULT: NEGATIVE MEDICAL MANAGEMENT: * Clinical Breast Exam and Breast Awareness * Mammography * MRI * Risk Reduc
Slide 22: The Opportunity
The Opportunity
Slide 23: Market Research Shows High Interest Level in riskScore
91% 9% 87% 13% 0% Would you change medical management based upon the combined score? How would this enhancement impact the competitive advantage of myRisk relative to other panel tests? Market Research Shows High Interest Level in riskScore
Slide 24: Physicians Believe riskScore Provides Incremental Value
91% 87% Physicians Believe riskScore Provides Incremental Value “If it gets marketed to the vast public, then I think Myriad will have a test that nobody else has.” “riskScore adds another piece of the puzzle. The sum of all information adds to an increased risk.“ "This is the most valuable thing a
Slide 25: Provides Reason for Preventive Care Doctors To Go Deeper
91% 87% Provides Reason for Preventive Care Doctors To Go “Deeper” 15M Patient Preventive Care Market From the “trusted advisor” in hereditary cancer Given low positive rate, average preventive care physician only looks for “neon light” patients EVERY patient will now have an individualized assessme
Slide 26: Myriad Will Continue to Be a Scientific Pioneer
91% 87% Myriad Will Continue to Be a Scientific Pioneer 15M Patient Preventive Care Market Commercially available as of today SNP Panel validation to be presented at National Society of Genetic Counselors annual meeting Combined validation (SNP Panel + Tyrer-Cuzick) presented at San Antonio Breast C